Management of worsening multiple sclerosis with mitoxantrone: A review

Clinical Therapeutics

Volumn 28, Issue 4, 2006, Pages 461-474

  Fox, Edward J ^a  

^a Multiple Sclerosis Clinic of Central Texas   (United States)

Author keywords

mitoxantrone; multiple sclerosis; Novantrone

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; BETA1A INTERFERON; BETAMETHASONE; CORTICOSTEROID; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; PLACEBO; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; AMENORRHEA; ANEMIA; APHTHOUS STOMATITIS; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; COCHRANE LIBRARY; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DERMATOMYCOSIS; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE EXTRAVASATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LEUKEMIA; LEUKOPENIA; LIVER METABOLISM; LOGISTIC REGRESSION ANALYSIS; MACROPHAGE; MEDLINE; MENINGITIS; MENORRHAGIA; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PHARYNGITIS; PROPHYLAXIS; RANDOMIZATION; RELAPSE; RHINITIS; SCREENING; SEPTIC SHOCK; STOMACH PAIN; T LYMPHOCYTE; THROMBOCYTOPENIA; URINALYSIS; URINARY TRACT INFECTION; CONTROLLED CLINICAL TRIAL; PATHOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS, PHASE II; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; MITOXANTRONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 33745285962     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.04.013     Document Type: Article

References (69)

1. Just the Facts: 2005-2006. Frequently Asked Questions About Multiple Sclerosis and the National MS Society. Available at: . Accessed December 20, 2005.
2. (Suppl). Weinshenker B.G. Natural history of multiple sclerosis. Ann Neurol. 36 (1994) S6-S11
3. Annapurna A., Kumar V.K., Rao P.M., et al. Multiple sclerosis: The disease and its treatment. Indian J Pharmacol. 34 (2002) 3-15
4. Chofflon M. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?. BioDrugs 19 (2005) 299-308
5. Paolillo A., Coles A.J., Molyneux P.D., et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Cam path 1H. Neurology 53 (1999) 751-757
6. Pender M.P., and Wolfe N.P. Prevention of autoimmune attack and disease progression in multiple sclerosis: Current therapies and future prospects. Intern Med J. 32 (2002) 554-563
7. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N Engl J Med. 343 (2000) 938-952
8. Weinshenker B., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 112 (1989) 133-146
9. Smith K.J., and McDonald W.I. The pathophysiology of multiple sclerosis: The mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lord B Biol Sci. 354 (1999) 1649-1673
10. San Francisco, Calif. Abstract. Arnold D.L. The unique roles of inflammation and degenerative processes in the pathology of MS: Insights from MR studies. Program and abstracts of the Annual Meeting of the Americas Committee for Research and Treatment in Multiple Sclerosis (October 19, 2003)
11. Lublin F.D., Reingold S.C., and National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46 (1996) 907-911
12. Sadovnick A.D., Armstrong H., Rice G.P., et al. A population-based study of multiple sclerosis in twins: Update. Ann Neurol. 33 (1993) 281-285
13. Calabresi P.A. Considerations in the treatment ofrelapsing-remitting multiple sclerosis. Neurology 58 Suppl 4 (2002) S10-S22
14. Avonex [package insert] (2005), Biogen Idec, Cambridge, Mass
15. Betaseron [package insert] (2003), Berlex, Inc, Montville, NJ
16. Rebif [package insert] (2004), Serono, Inc, Rockland, Mass
17. Copaxone [package insert] (2002), Teva Neuroscience, Kansas City, Mo
18. Johnson K.P., Brooks B.R., Cohen J.A., et al., Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50 (1998) 701-708
19. Johnson K.P., Brooks B.R., Cohen J.A., et al., Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebocontrolled trial. Neurology 45 (1995) 1268-1276
20. Wolinsky J.S., Narayana P.A., Johnson K.P., and Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler 7 (2001) 33-41
21. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
22. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
23. Kappos L., Polman C., Pozzilli C., et al., European Study Group on Interferon beta-1b in Secondary Progressive MS. Final analysis of the European multicenter trial on IFNbeta-16 in secondary progressive MS. Neurology 57 (2001) 1969-1975
24. Panitch H., Miller A., Paty D., Weinshenker B., and North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 63 (2004) 1788-1795
25. Jacobs L.D., Beck R.W., Simon J.H., et al., CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 343 (2000) 898-904
26. Jacobs L.D., Cookfair D.L., Rudick R.A., et al., Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39 (1996) 285-294
27. Cohen J.A., Cutter G.R., Fischer J.S., et al., IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59 (2002) 679-687
28. PRISMS (Prevention of Relapses and Disability by Interferon beta-1 aSubcutaneously in Multiple Sclerosis) Study Group. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
29. PRISMS Study Group and the University of British Columbia MS/ MRI Analysis Group. PRISMS-4: Long-term efficacy of interferonbeta-1a in relapsing MS. Neurology 56 (2001) 1628-1636
30. Panitch H., Goodin D.S., Francis G., et al., EVIDENCE Study Group. Evidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59 (2002) 1496-1506
31. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferonbeta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1 a in secondary progressive MS: Clinical results. Neurology 56 (2001) 1496-1504
32. Bastianello S., Pozzilli C., D'Andrea F., et al. A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year. Can J Neurol Sci. 21 (1994) 266-270
33. Millefiorini E., Gasperini C., Pozzilli C., et al. Randomized placebocontrolled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome. J Neurol. 244 (1997) 153-159
34. van de Wyngaert F.A., Beguin C., D'Hooghe M.B., et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg. 101 (2001) 210-216
35. Edan G., Miller D., Claret M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62 (1997) 112-118
36. Hartung H.P., Gonsette R., König N., et al., Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
37. Miami Beach, Fla. Abstract 546.008. Fox E., Al-Sabbagh A., and Bennett R. Safety and tolerability of Novantrone (mitoxantrone) in clinical practice: Status report from the Registry to Evaluate Novantrone Effects in Worsening MS (RENEW) study. Program and abstracts of the 57th Annual Meeting of the American Academy of Neurology (April 9-16, 2005)
38. Leppert D., Waubant E., Burk M.R., et al. Interferon beta-16 inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 40 (1996) 846-852
39. Rudick R.A., Ransohoff R.M., Lee J.C., et al. In vivo effects of interferon beta1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50 (1998) 1294-1300
40. Miller D.H., Molyneux P.D., Barker G.J., et al., European Study Group on Interferon-beta1b in Secondary Progressive Multiple Sclerosis. Effect of interferon-beta16 on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol. 46 (1999) 850-859
41. Li D.K., Zhao G.J., Paty D., and University of British Columbia MS/ MRI Analysis Research Group. The SPECTRIMS Study Group. Randomized controlled trial of interferonbeta-1a in secondary progressive MS: MRI results. Neurology 56 (2001) 1505-1513
42. Teitelbaum D., Meshorer A., Hirshfeld T., et al. Suppression of experimental allergic encephalomyelitis by a syn thetic polypeptide. Eur J Immunol. 1 (1971) 242-248
43. Comi G., Filippi M., Wolinsky J.S., and European/Canadian Glatiramer Acetate Study Group. European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 49 (2001) 290-297
44. Neuhaus O., Archelos J.J., and Hartung H.P. Immunomodulation in multiple sclerosis: From immunosuppression to neuroprotection. Trends Pharmacol Sci. 24 (2003) 131-138
45. Summary. Available at:. National M.S. Society Information Sourcebook. The National MS Society's Disease Management Consensus Statement. Accessed (December 20, 2005). http://www.nationalmssociety.org/pdf/sourcebook/consensus_summary.pdf
46. Novantrone [package insert] (2003), Serono, Inc, Rockland, Mass
47. Watson C.M., Davison A.N., Baker D., et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol. 13 (1991) 923-930
48. Mustafa M., Diener P., Sun J.B., et al. Immunopharmacologic modulation of experimental allergic encephalo myelitis: Low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cellmediated myelin-directed autoimmunity. Scand J Immunol. 38 (1993) 499-507
49. Levine S., and Gherson J. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tis sues. Int J Immunopharmacol 8 (1986) 999-1007
50. Fidler J.M., DeJoy S.Q., and Gibbons Jr. J.J. Selective immunomodulation bythe antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol. 137 (1986) 727-732
51. Fidler J.M., DeJoy S.Q., Smith III F.R., and Gibbons Jr. J.J. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol. 136 (1986) 2747-2754
52. Ehninger G., Proksch B., Heinzel G., and Woodward D.L. Clinical pharmacology of mitoxantrone. Cancer Treat Rep. 70 (1986) 1373-1378
53. Gonsette R.E. Mitoxantrone in progressive multiple sclerosis: When and how to treat?. J Neurol Sci. 206 (2003) 203-208
54. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
55. Krapf H., Morrissey S.P., Zenker O., et al., MIMS Study Group. Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial. Neurology 65 (2005) 690-695
56. Goodin D.S., Amason B.G., Coyle P.K., et al., Therapeutics and Technology Assessment Subcommit tee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 1332-1338
57. Olindo S., Guillon B., Helias J., et al. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol. 9 (2002) 287-291
58. Ghalie R.G., Edan G., Laurent M., et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59 (2002) 909-913
59. Vicari A.M., Ciceri F., Folli F., et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 12 (1998) 441-442
60. Ghalie R.G., Mauch E., Edan G., et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler. 8 (2002) 441-445
61. Brassat D., Recher C., Waubant E., et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 59 (2002) 954-955
62. Heesen C., Bruegmann M., Gbdamosi J., et al. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 9 (2003) 213-214
63. Cattaneo C., Almici C., Borlenghi E., et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 17 (2003) 985-986
64. Delisse B., de Seze J., Mackowiak A., et al., G-SEP. Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 10 (2004) 92
65. Novoselac A.V., Reddy S., and Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 18 (2004) 1561-1562
66. Voltz R., Starck M., Zingler V., et al. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: A case report out of 644 treated patients. Mult Scler. 10 (2004) 472-474
67. [in French]. Nollet S., Berger E., Deconinck E., et al. Acute leukaemia in two multiple sclerosis patients treated with mito xantrone. Rev Neurol (Paris) 162 (2006) 195-199
68. Hawker K.S., and Frohman E.M. Bladder, bowel, and sexual dysfunction in multiple sclerosis. Curr Treat Options Neurol. 3 (2001) 207-214
69. Yuruktumen A., Karcioglu O., Topacoglu H., and Arslan E.D. Acute renal failure associated with clysfunction ing detrusor muscle in multiple sclerosis. Adv Ther. 21 (2004) 343-347